Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study

Elotuzumab, an immunostimulatory monoclonal antibody targeting SLAMF7, selectively kills multiple myeloma (MM) cells and synergizes with pomalidomide (pom). The primary analysis (minimum follow-up [FU]: 9.1 mo) of the open-label, randomized ELOQUENT-3 study (NCT02654132) demonstrated a median progression-free survival (PFS) of 10.3 mo for elotuzumab plus pom and dexamethasone (dex; EPd) vs 4.7 mo for pom and dex (Pd) alone (hazard ratio [HR] 0.54, p=0.008). Preliminary analysis of overall survival (OS) suggested a trend in favor of EPd (Dimopoulos MA et al. N Engl J Med 2018). Based on these data, EPd was approved in the USA for the treatment of adult patients (pts) with MM and ≥2 prior therapies including lenalidomide (len) and a proteasome inhibitor (PI). Aims: This non-prespecified analysis was conducted after a minimum FU of 18.3 mo to provide a descriptive assessment of OS with EPd vs Pd in ELOQUENT-3. PFS and safety were also assessed.